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Objectives: To perform a health economics evaluation for insulin injection pen-
needle with different lengths in diabetic patients in China. MethOds: With the 
relationship between HbA1C level and diabetes-related complications obtained from 
literature, cost-benefit analysis was applied to evaluate the net cost saving (includ-
ing the cost of needles and cost of complications and adverse events treatment) of 
shorter pen-needle compared to the longer one, from the perspective of society. The 
unit costs were retrieved from published sources and outcomes of the effectiveness 
were derived from meta-analysis of relevant literatures related to different lengths 
insulin pen-needle. One-way sensitivity analysis was conducted to demonstrate the 
robustness of results. Results: The meta-analysis showed that compared to the 
longer needle, the shorter one decreased HbA1C by an average of 0.11% and reduced 
the risk of hypoglycaemic events by 17%. A net saving of $27 per patient based on 
shorter needle resulted from decreased adverse events, while the costs of needles 
were increased by $9 during the trial time. If the retinopathy was included, shorter 
needle produced a net saving of $320 per patient due to decreased complications, 
and the economic evaluation revealed shorter needle can totally save $338 per 
patient compared to the longer one. If without retinopathy, the net saving was $129 
per patient due to decreased complications, and the totally saving was $147 per 
patient. Sensitivity analysis showed that the results were stable. cOnclusiOns: 
Current findings indicate that shorter insulin injection pen-needle lead to a decreas-
ing of complications and adverse reaction compared to longer needle, and subse-
quently could lead to a reduction in health costs.
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Objectives: To investigate the burden of type 1 diabetes mellitus (T1DM) in France 
associated with non-adherence to clinical guidelines using the IMS CORE Diabetes 
Model (CDM) and clinical data from the IMS Lifelink Diabetes Cohort. MethOds: 
The CDM is a health economic model based on 17 inter-dependent sub-models 
that simulate micro- and macrovascular complications associated with diabetes. 
Physiological parameter inputs such as HbA1c, blood lipids, body mass index (BMI), 
and systolic blood pressure (SBP) were taken from real-life data and compared with 
guidelines from the “Haute Autorité de Santé”. T1DM patients (age ≥ 18) who visited 
a general physician between May 2011 and May 2014 and have received at least 
one insulin prescription were included in the analysis. Costs and outcomes were 
discounted at 4% per annum. Costs of complications were taken from published 
sources. Results: A cohort of 605 T1DM patients (43% male) was analyzed. Mean 
age at first visit was 58 years, HbA1c was 7.8%, SBP was 132 mmHg, and BMI was 28 
kg/m2. Smokers represented 23% of the cohort. Results from economic modeling 
using the CDM suggest that for prevalent T1DM patients in France, potential sav-
ings for the health care system associated with meeting the therapeutic guidelines 
would be on average of 1,661 EUR per patient from a lifetime perspective. Most of 
the savings would come from the prevention of renal complications. Any new com-
plication would be delayed by 2.4 months on average. cOnclusiOns: The “Haute 
Autorité de Santé” recommends that T1DM patients maintain their HbA1c lower 
than 7.5%, SBP lower than 130 mmHg, BMI lower than 25 kg/m2 and quit smoking. 
Our results showed that these recommendations were not strictly followed among 
T1DM patients in France. Better adherence to the T1DM guidelines would lead to 
cost savings in the French health care system and improved patient outcomes.
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Objectives: Canagliflozin is a novel drug for treatment of diabetes belonging 
to the drug class known as sodium glucose co-transporter-2 (SGLT2) inhibitors 
which method of action is insulin independent. Canagliflozin has been shown to 
not only reduce glucose levels, but also weight and blood pressure. The objective is 
to evaluate the cost-effectiveness of canagliflozin 100mg in dual therapy (add-on 
to metformin) compared to sitagliptin and glimepiride, in triple therapy (add-on 
to metformin and sulfonylurea) compared to sitagliptin and as an insulin add-on 
compared to dapagliflozin in the Czech Republic setting from a payer perspec-
tive. MethOds: The IMS CORE Diabetes Model was used to evaluate the cost-
effectiveness of canagliflozin using clinical trial data and network meta-analysis 
data, combined with Czech Republic specific data, where available. Results: The 
cost-effectiveness analyses indicate that in dual therapy when compared with 
sitagliptin and glimepiride, canagliflozin 100mg is found to be cost-effective with 
an incremental cost-effectiveness ratio (ICER) of 242,783 Kč per QALY gained and 
626,939 Kč per QALY gained, respectively. In triple therapy when compared to sit-
agliptin, canagliflozin 100mg is found to be cost-effective with an ICER of 335,759 
Kč per QALY gained. As an add-on to insulin (with or without metformin), canagli-
flozin compared to dapagliflozin appears to be cost-effective with an ICER of 375 Kč 
per QALY gained. A wide range of deterministic sensitivity analyses revealed that 
in the majority of scenarios, canagliflozin remained cost-effective with ICERs well 
below the willingness-to-pay threshold of 1,100,000 Kč per QALY. cOnclusiOns: 
Canagliflozin 100mg represents a cost-effective option for the treatment of type 2 
diabetes in the Czech Republic. Canagliflozin 100mg offers greater health benefits 
than the included alternatives in this study, at a cost that provides good value 
for money.
pharmaceutical and blood glucose reagent strips. All measurements were obtained 
at individual level. Results: The raw prevalence of diabetes was 6.7%. All patients 
were stratified into four morbitity groups. The first group corresponded to the ini-
tial state (CRG 1-4); the second group included the core multimorbidity patients in 
the intermediate and advanced stages (CRG 5-7); the third group included patients 
with diabetes and malignancies; the last group was of patients with catastrophic 
statuses, manly ERSD. The most common comorbitities in the patient group for 
CRG 5 to 7 were hypertension (47% - 97%), dislipemia (50.9% - 59%) and cardiovas-
cular disease (18% - 39.9%). The average cost of insulin was € 117.1. The average 
cost of oral antidiabetic agents secretagogues was € 15.2 and was highest in the 
CRG 5 to 7 group at € 16.3. The average cost of non-secretagogue oral antidiabetic 
agents was € 212.9 and was highest in the CRG 5 to 7 group at € 232.8. The total 
average cost was € 476.5 in CRG 1-4 group, € 1350.5 in CRG 5-7 group, € 2174.1 in 
CRG 8 group and € 2840.5 in CRG 9 group. cOnclusiOns: Diabetes is charac-
terised by a strong presence of other chronic conditions and events related to 
its development throughout life. This multimorbidity has a great impact on the 
pharmaceutical cost.
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Objectives: Estimate the economic impact of the early microbiological culture 
in the cost-reduction associated to the attendance process of the infected ulcers 
in diabetic foot through an economic model based on a Monte Carlo simula-
tion. MethOds: Economic model of Monte Carlo simulation in two steps: The 
first step was a descriptive and longitudinal study. Were included diabetic subjects 
with infected ulcers in diabetic foot, patients were initially treated in Emergency 
Room of Mexican IMSS’ secondary level hospital in a period from January 1st to 
April 30th2010. Results: Micro-costing Analysis Results: Total costs for the sample 
were $502,438.04 USD, the mean cost per patient was $7,177.69 (±$5,043.51) USD, 
the median cost was $6,422.99 (p25 $3,502.93; p75 $9,298.33). 72.75% ($365,527.45) 
of the total cost was related to hospital stay. 10.6% ($53,240.86) of the expenditure 
during treatment was associated to wound healing care, 9.98% ($50,132.94) surger-
ies, 1.87% ($9,389.27), anti-diabetic drugs and concomitant chronic diseases. 1.79% 
($9,008.47) to clinical chemistry tests, 1% ($5,405.98) antibiotics, similar percentage 
to the imaging studies ($5,000.08), 0.66% ($3,309.88) acute phase reactants, 0.19% 
($965.65) microbiologic cultures, and the lowest percentage was destined to intra-
venous fluids. Monte carlo Modelling Results: Antibiotic cost analysis showed: If 
the physician takes a secretion sample in the first 48 hours of the patient admission 
in emergency room and begin the empirical antibiotic treatment, and modifies the 
criteria according microbiological results from the culture, the cost will be reduced 
(through antibiotic expenditure) 9 to 15%. The reduction could be 20 to 32% associ-
ated to reduce the hospital stay days. The total cost for the attendance process could 
be reduced 10 to 25%. cOnclusiOns: According Monte Carlo Modelling results the 
early microbiological culture as the base of antibiotic selection can reduce treat-
ment cost in more than 30%.
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Objectives: To evaluate the outcomes and current costs of 4 different sce-
narios of diabetic foot ulcers (DFU) treatment in Russian current medical prac-
tice. MethOds: We developed a decision tree model estimating annual number 
of outcomes (major and minor amputations) and costs for 4 simplified possible 
scenarios of medical care: 1) outpatient diabetic foot clinic, 2) non-specialized 
outpatient care, 3) cessation of the outpatient treatment by patient after the sec-
ond visit and 4) care provided only at hospital (without previous visits to any 
outpatient clinic). The distribution of the patient cohort (1000 patients) among the 
scenarios and rates of possible events were based on published Russian data and 
experts’ survey. Costs were calculated from the overall governmental budget point 
of view and included inpatient and outpatient care for DFU treatment, total con-
tact casting, medications and dressings provided in the outpatient care, prosthetic 
devices and services. Cost data was derived from published retrospective study 
comparing provision of care to DFU patients in specialized and non-specialized 
clinics in Russia and reimbursement rates in public medical insurance and social 
care. Results: The lowest rate of amputations per patient (0.07 for minor and 0.01 
for major) is expected for those receiving treatment in the outpatient diabetic foot 
clinic with mean annual cost € 279.68 per patient. The highest costs (€ 1141.17) and 
amputation rates (0.29 for minor and 0.19 for major) per patient are observed in 
the group treated at hospital only. The minor amputation rate and annual costs are 
higher for patients following non-specialized outpatient care than for those ceas-
ing the outpatient treatment – 0.11 vs 0.09 and € 449.82 vs € 381.30, and the reverse 
was observed for the rate of major amputations - 0.03 vs 0.06. cOnclusiOns: 
Referring DFU patients to the outpatient diabetic foot clinics as early as possible 
appears to be the most cost-effective way of treating them.
